Martin David Harp

The trial will be conducted by French tissue bank, TBF Génie Tissulaire.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

TOUR006 is an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED).

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Canadian and Australian ophthalmologists and optometrists are looking ahead at the impact increased wildfire smoke can have on the ocular surface.

The trial is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects with cystoid macular edema.

The scholarships will be worth $1000 each and “aim to recognize innovation in myopia management and specialty contact lenses.”

This marks the 22nd time, and the 20th consecutive year, Bascom Palmer has received the No. 1 ranking by US News & World Report since the publication began surveying US physicians for its annual "Best Hospitals" rankings 34 years ago.

The trial will be an open-label trial in partnership with Tufts Medical Center. OK-101 is also being developed for use in dry eye disease.

The month will be dedicated to educating families on the importance of healthy vision and early access to healthcare.

The company also provided an update on tarcocimab development program for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

With lawsuits looming over the issue, the FDA has updated the label on Horizon Pharmaceutical’s drug for thyroid eye disease to include risks associated with hearing loss.

SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.

The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.

The Kansas-based company specializes in ophthalmic surgical equipment and services.

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.

The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.

The India-based pharmaceutical company is taking its first steps into ophthalmology with the announcement.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

The funds will be used to further develop the company’s Calibreye System that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.

Maria Montero, MD, of Orbis sits down with David Hutton of Ophthalmology Times, to discuss technology and training for cataract surgery, including simulation, and telementoring.

Kaushal Solanki, PhD, discusses how ophthalmologists can now use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy.

The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

SBI-100 is a cannabinoid receptor type 1 (CB1R) agonist administered topically onto the eye to reduce IOP and treat glaucoma.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

EverPatch is described by the company as the world's first non-degradable, synthetic tissue substitute for ophthalmic surgery.